Cowen and Company started coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA) in a research report released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares after opening at $6.16 on last trade day and at the end of the day closed at $6.59. Company price to sales ratio in past twelve months was calculated as 6410.53 and price to cash ratio as 7.79. Idera Pharmaceuticals Inc (NASDAQ:IDRA) showed a positive weekly performance of 14.41%.
TheStreet Quant Ratings rates Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares advanced 3.55% in last trading session and ended the day on $18.67. VNDA return on equity ratio is recorded as -76.90% and its return on assets is -15.00%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) yearly performance is 50.44%.
Albany Molecular Research (NASDAQ:AMRI) was upgraded by equities research analysts at TheStreet from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Analyst Ratings.Net reports. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares moved up 3.77% in last trading session and was closed at $19.55, while trading in range of $18.71 – $19.55. Albany Molecular Research, Inc. (NASDAQ:AMRI) year to date (YTD) performance is 93.95%.
Relypsa Inc (NASDAQ:RLYP), which went public in November last year, reported a loss of 68 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 74 cents. Fourth quarter 2013 loss was also narrower than the year-ago loss. The narrower loss was primarily due to a decline in the fair value of the convertible preferred stock warrants as a result of the company’s initial public offering. Relypsa Inc (NASDAQ:RLYP) weekly performance is 11.23%. On last trading day company shares ended up $46.05. Relypsa Inc (NASDAQ:RLYP) distance from 50-day simple moving average (SMA50) is 27.73%. Analysts mean target price for the company is $46.00.
Leave a Reply